GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed

Regulatory & Legal View source PDF Explain this filing

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹2476.00

prior close

₹2461.40

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%-1.2% vs market

Pharmaceuticals peers, median of 156sector-0.0%-0.8% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Midcap 150 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.1

15m

-0.2

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8+0.4-1.2-0.0-0.8

Next day

+0.4+1.4-1.0+0.7-0.3

-0.8+1.3-2.1+0.2-1.1

+0.2+1.0-0.9+0.4-0.3

-0.8+1.5-2.3+0.9-1.7

-3.1-0.4-2.7-0.6-2.5

-3.6-1.5-2.1-2.2-1.4

15d

-6.8-5.7-1.1-6.7-0.1

-3.1-4.6+1.5-6.7+3.6

+2.2-3.6+5.8-8.0+10.3

-6.2-10.8+4.6-13.7+7.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

GlaxoSmithKline Pharmaceuticals has received an order dated 31st December 2025 from the Assistant Commissioner of State Tax, Mumbai, Maharashtra, for financial year 2021-22. The total demand is Rs. 35,07,895, broken down as Rs. 18,16,196 in tax, Rs. 15,10,080 in interest, and Rs. 1,81,619 in penalty. The demand relates to GST credit mismatch issues between the company's GST returns and supplier-reported details. The company has stated there is no impact on its financial operations and that it is evaluating the order to take appropriate action.

Likely market impact

The demand amount of ~Rs. 35 lakh is immaterial relative to GSK Pharma's overall size and should not materially affect financials or stock price. Shareholders should note the company is still evaluating whether to contest or pay, so the final outcome is pending.